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The only variant Creutzfeldt-Jakob disease (vCJD)
patient identified in the United States died in 2004, and the
diagnosis was confirmed by analysis of autopsy tissue. The
patient likely acquired the disease while growing up in Great
Britain before immigrating to the United States in 1992.
Additional vCJD patients continue to be identified outside
the United Kingdom, including 2 more patients in Ireland,
and 1 patient each in Japan, Portugal, Saudi Arabia, Spain
and the Netherlands. The reports of bloodborne transmis-
sion of vCJD in 2 patients, 1 of whom was heterozygous for
methionine and valine at polymorphic codon 129, add to the
uncertainty about the future of the vCJD outbreak.
V
ariant Creutzfeldt-Jakob disease (vCJD) was first
reported in 1996 in the United Kingdom and has been
causally linked to eating cattle products contaminated with
the bovine spongiform encephalopathy (BSE) agent (1–3).
Both vCJD and BSE are rapidly progressive neurodegen-
erative disorders classified as transmissible spongiform
encephalopathies (TSEs) or prion diseases. TSEs are char-
acterized by 1) incubation periods measured in years, 2)
presence in the brain of an unconventional agent called a
prion, 3) absence of inflammatory reaction, and 4) a neu-
ropathologic feature consisting typically of spongiform
lesions, astrogliosis, and neuronal loss. vCJD is distin-
guished from the more common TSE in humans, sporadic
CJD, by the younger median age (28  years and 68 years,
respectively) of the patients and by its clinical and neu-
ropathologic manifestations. 
In 2002, the likely occurrence of vCJD was reported in
a 22-year-old woman living in Florida and represented the
first detection of the disease in North America (4). In this
report, we describe this patient’s illness and provide an
update on the epidemiologic features of the ongoing vCJD
outbreak worldwide, including recent reports of blood-
borne transmission of vCJD.
Case Report
In early November 2001, the patient in Florida was
evaluated for depression and memory loss that adversely
affected her work performance and may have contributed
to a traffic ticket she received for failure to yield the right
of way at a traffic sign. In December 2001, the patient
developed involuntary movements, gait disturbances, dif-
ficulty dressing, and incontinence. The following month,
she was taken to a local emergency department; a comput-
ed tomographic scan of her brain showed no abnormalities,
a diagnosis of panic attack was made, and antianxiety
medications were prescribed.
In late January 2002, the patient was transported to the
United Kingdom, where her mother resided. During the
ensuing 3 months, the patient’s motor and cognitive
deficits worsened, which caused falls resulting in minor
injuries; she had difficulty taking care of herself, remem-
bering her home telephone number, and making accurate
mathematical calculations. She also experienced confu-
sion, hallucination, dysarthria, bradykinesia, and spastici-
ty. An electroencephalogram evaluation showed no
abnormalities, but a brain magnetic resonance imaging
(MRI) study showed the characteristic signal abnormali-
ties in the pulvinar and metathalamic regions suggestive of
vCJD. Western blot and immunohistochemical analyses of
tonsillar biopsy tissue demonstrated the presence of pro-
tease-resistant prion protein, which supported the diagno-
sis of vCJD. By September 2002, the patient was
bedridden. An experimental treatment with quinacrine was
given to the patient for 3 months, but she showed little
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and died in June 2004, ≈32 months after illness onset. 
The patient was born in Great Britain in 1979 and
immigrated to the United States with her family in 1992.
She had no history of surgery or receipt of blood or blood
products, and she was never a blood donor. Consistent with
findings for vCJD patients in the United Kingdom associ-
ated with potential foodborne exposure, this patient was
homozygous for methionine at polymorphic codon 129 of
the prion protein gene. A full autopsy was performed, and
neuropathologic examination of brain tissue showed the
presence of florid plaques and severe cortical atrophy
(Figure 1). Immunohistochemical staining for the prion
protein showed numerous plaquelike formations along
with a synaptic staining pattern similar to that previously
described in other vCJD patients (Figure 2).
This patient is the only US resident with a confirmed
diagnosis of vCJD. She was likely exposed to BSE while
growing up in the United Kingdom from 1980 to 1992,
which suggests an incubation period of 9–21 years (Table).
The illness duration in this patient (≈32 months) was much
longer than the median illness duration for patients in the
United Kingdom with vCJD (14 months, range 6–40
months).
Updates on vCJD
As of early August 2005, 157 vCJD patients were
reported from the United Kingdom: 13 have been reported
from France, 3 from Ireland, and 1 each from Canada,
Italy, Japan, Portugal, Spain, the Netherlands, and the
United States (Figure 3). Similar to the vCJD patient from
the United States, 1 patient from Ireland and the patients
from Canada and Japan were likely exposed to the BSE
agent during their residence in the United Kingdom.
Preliminary information indicates that the Japanese patient
spent only ≈24 days in the United Kingdom. In addition,
the US National Prion Disease Pathology Surveillance
Center confirmed a vCJD diagnosis by analyzing a brain
biopsy sample from a 33-year-old Saudi man admitted to a
hospital in Saudi Arabia. Although detailed information on
this patient was not available, he may have visited the
United Kingdom, if at all, only for several days. Thus, the
patient likely contracted the disease in Saudi Arabia after
eating BSE-contaminated cattle products imported from
the United Kingdom.
Certain characteristics distinguishing vCJD from clas-
sic CJD raised early concerns about possible secondary
bloodborne spread of vCJD, especially in light of the lack
of experience with this newly emerged disease. Of specif-
ic concern was the detection of the agent in lymphoid tis-
sues and the possibility of prionemia as the agent spreads
from the gut to the brain. In 1997, to monitor for the pos-
sible bloodborne transmission of vCJD, researchers in the
United Kingdom began investigating recipients of blood
components obtained from donors who subsequently died
of vCJD (5). As of February 2004, 48 recipients were iden-
tified, including 18 who had survived for >4 years after
transfusion. Two of these 18 recipients had evidence of
bloodborne transmission of vCJD. One of the 2 recipients
was 62 years of age and had received 5 units of erythro-
cytes in 1996 (5). One of these units was traced to a 24-
year-old donor in whom vCJD developed >3 years after
the blood was donated. In 2002 (6.5 years after the trans-
fusion), vCJD developed in the recipient, who died 13
months after illness onset. An autopsy confirmed the diag-
nosis of vCJD.
RESEARCH
1352 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 9, September 2005
Figure 1. Histopathologic changes in frontal cerebral cortex of the
patient who died of variant Creutzfeldt-Jakob disease in the United
States. Marked astroglial reaction is shown, occasionally with rel-
atively large florid plaques surrounded by vacuoles (arrow in inset)
(hematoxylin and eosin stain, original magnification ×40).
Figure 2. Immunohistochemical staining of cerebellar tissue of the
patient who died of variant Creutzfeldt-Jakob disease in the United
States. Stained amyloid plaques are shown with surrounding
deposits of abnormal prion protein (immunoalkaline phosphatase
stain, naphthol fast red substrate with light hematoxylin counter-
stain; original magnification ×158).The second patient potentially linked with bloodborne
transmission of vCJD was an elderly person who received
a unit of erythrocytes in 1999. vCJD developed in the
donor of the unit 18 months after blood was donated (6).
The recipient died of a ruptured aortic aneurysm 5 years
after the transfusion. Tests of the patient’s spleen and cer-
vical lymph node detected protease-resistant prion protein
with a Western blot mobility pattern and glycoform ratio
similar to those seen in other vCJD patients. These results
and the absence of neurologic symptoms and brain patho-
logic findings indicated that this patient had a subclinical
vCJD infection. Prion protein gene sequencing showed
heterozygosity for methionine and valine at codon 129,
which indicated that persons not homozygous for methio-
nine (>50% of the population) can be infected by the vCJD
agent. 
In the United States, the risk of bloodborne transmis-
sion of vCJD is low because of the absence of indigenous
vCJD and the geographic-based donor deferral policy
instituted by the Food and Drug Administration in 1999.
This policy excludes from donating blood in the United
States persons who resided in or had extended visits to the
United Kingdom or other European countries during peri-
ods of greatest concern for BSE exposure (7).
The exact incubation period for foodborne vCJD is
unknown. However, a range of possible incubation periods
was estimated for 4 vCJD patients who likely acquired the
disease during their residence in the United Kingdom and
for 5 vCJD patients reported as part of a cluster in
Leicestershire, England (Table). The median of the esti-
mated range of incubation periods for these 9 vCJD
patients was 13 years. The incubation period for the vCJD
patient linked to bloodborne transmission was shorter (6.5
years). This finding could be the result of direct transmis-
sion of the agent into the bloodstream and adaptation of the
agent to the human population, thus reducing or eliminat-
ing the species barrier (Table).
Conclusions
Patients with vCJD can be distinguished from patients
with the more common sporadic CJD by their younger
median age at death (28 years and 68 years, respectively),
predominantly psychiatric manifestations at illness onset,
delayed appearance of frank neurologic signs, absence of
a diagnostic electroencephalographic pattern, presence of
the pulvinar sign on MRI, and a longer median illness
duration (<6 and 14 months, respectively) (3,8). Almost
all vCJD patients have died before 55 years of age, com-
pared with only ≈10% of sporadic CJD patients. The most
striking early neurologic manifestation in some vCJD
patients was painful sensory symptoms (dysesthesia or
paresthesia). Other neurologic signs, such as chorea, dys-
tonia, and myoclonus, commonly develop late in the
course of vCJD. An MRI result with symmetrically
increased signal intensity in the pulvinar region relative to
the signal intensity in other deep and cortical gray mater
areas has been reported in >75% of vCJD patients. The
presence of this MRI feature, known as pulvinar sign, may
suggest a vCJD diagnosis in the appropriate clinical con-
text. A prominent, early involvement of lymphoid tissues
has enabled a reasonably accurate premortem diagnosis of
vCJD, using tonsillar biopsy. However, a more definitive
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Figure 3. Number of deceased variant Creutzfeldt-Jakob disease
patients worldwide (150 from the United Kingdom and 15 outside
the United Kingdom) by year of death, June 2005.diagnosis of vCJD may require testing autopsy brain
tissues.
In June 2005, the US Department of Agriculture con-
firmed BSE in an ≈12-year-old cow born and raised in
Texas. This is the first time an indigenous BSE case was
detected in the United States. A previous BSE-positive
cow identified in Washington State was imported from
Canada (3) where, to date, 4 additional BSE cases have
been identified. The identification of BSE in North
America and the likelihood of bloodborne transmission of
vCJD underscore the need to continue surveillance to mon-
itor the occurrence of vCJD in the United States (3). The
case-patient described in this report illustrates the need for
physicians to remain vigilant for the possibility of vCJD in
patients with the signs and symptoms described.
Physicians should report suspected vCJD cases to local
and state health departments. Because the clinical manifes-
tation of vCJD can overlap that of sporadic CJD, brain
autopsies should be sought in all suspected cases to estab-
lish the diagnosis and to help monitor the occurrence of
vCJD and other potentially emerging forms of CJD. Free
state-of-the art prion disease diagnostic testing is available
from the National Prion Disease Pathology Surveillance
Center (http://www.cjdsurveillance.com), which was
established to facilitate autopsy performance and testing
(8). Physicians are encouraged to use the services of the
surveillance center to evaluate neuropathologic changes in
their patients with suspected or clinically diagnosed prion
disease. 
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